缩宫素在瘢痕子宫再次妊娠孕妇中的应用及效果分析

Application of oxytocin in repregnancy women with scar uterus and its effect analysis

目的探讨缩宫素在瘢痕子宫再次妊娠孕妇阴道试产过程中应用对分娩结局的影响。方法 372例妊娠合并瘢痕子宫阴道试产孕妇,将试产过程中需要使用缩宫素且产妇自愿接受的设为研究组(159例),将试产过程中需要使用缩宫素但产妇拒绝使用的设为对照组(213例)。比较两组孕妇阴道试产成功率、产程、新生儿窒息率、产时出血率等。结果研究组阴道试产成功率为71.7%,高于对照组的61.5%,差异具有统计学意义(P<0.05)。研究组第一产程及第二产程均短于对照组,差异有统计学意义(P<0.05)。两组产道裂伤率、产时出血率、新生儿窒息率比较差异均无统计学意义(P>0.05)。结论妊娠合并瘢痕子宫孕妇选择阴道试产中使用缩宫素引产是相对安全的,可缩短产程,提高阴道分娩率,同时未增加不良分娩结局的发生率。

Objective To discuss the effect of oxytocin on delivery outcome in repregnancy women with scar uterus during vaginal trial production. Methods There were 372 pregnancy women with scar uterus undergoing vaginal trial production. Pregnant women voluntarily accepting oxytocin in trial production process were taken as the control group（159 cases）, and pregnant women refusing use of oxytocin in trial production process were taken as the control group（213 cases）. Comparison were made on successful rate of vaginal delivery, course of labor, rate of neonatal asphyxia and rate of intrapartum hemorrhage in two groups. Results The research group had higher successful rate of vaginal delivery as 71.7% than 61.5% in the control group, and the difference was statistically significant（P〈0.05）. The research group had shorter first and second stage of labor than the control group, and the difference was statistically significant（P〈0.05）. Both groups had no statistically significant difference in soft birth canal laceration rate, rate of intrapartum bleeding, rate of neonatal asphyxia（P〈0.05）. Conclusion In pregnant women with scar uterus, oxytocin is relatively safe to choose in vaginal trial production, and it can shorten the course of labor, improve the rate of vaginal delivery, without increasing the incidence of adverse labor outcomes.